⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9635656 | 0.84 | KMT2A (0.39) | — | |
| SCHEMBL1001730 | 0.80 | — | — | |
| SCHEMBL179219 | 0.77 | — | — | |
| SCHEMBL353456 | 0.73 | — | — | |
| SCHEMBL13343501 | 0.73 | KMT2A (0.50) | — | |
| SCHEMBL22207679 | 0.73 | KMT2A (0.50) | — | |
| SCHEMBL12020568 | 0.73 | KMT2A (0.46) | — | |
| SCHEMBL14592158 | 0.73 | KMT2A (0.46) | — | |
| SCHEMBL1404404 | 0.71 | KMT2A (0.37) | — | |
| Hydrochloric Acid SCHEMBL31693577 | 0.71 | PKM (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317767-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2024-09-26 | — | — | US | disclosed |
| US-12024523-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2024-07-02 | — | — | US | disclosed |
| US-20230219967-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2023-07-13 | — | — | US | disclosed |
| US-11691978-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| US-20210355127-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2021-11-18 | — | — | US | disclosed |
| EP-3670499-B1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-11001589-B2 | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (SE) | 2021-05-11 | — | — | US | disclosed |
| EP-3670499-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | Astrazeneca AB (SE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200157113-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2020-05-21 | — | — | US | disclosed |
| CN-107646036-B | Pyrazole derivatives useful as inhibitors of 5-lipoxygenase activating protein (FLAP) | 阿斯利康(瑞典)有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH | 2018-05-17 | — | — | US | disclosed |
| EP-3292105-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | AstraZeneca AB (SE) | 2018-03-14 | — | — | EP | disclosed |
| CN-107646036-A | Pyrazole derivatives useful as inhibitors of 5-lipoxygenase activating protein (F L AP) | 阿斯利康(瑞典)有限公司 | 2018-01-30 | — | — | CN | disclosed |
| WO-2016187050-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5]OXADIAZOLO[3',4':5,6] PYRAZIONO[2,3-B]INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016177703-A1 | PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | WO | disclosed |
| EP-1660467-B1 | 2-(4-AMINO-1,2,5-OXADIAZOL-4-YL)-IMIDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-12-07 | — | — | EP | disclosed |
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157476-B2 | Aminofurazan compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1660467-A2 | AMINOFURAZAN COMPOUNDS AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019190-A2 | (4 -AMINO -1,2, 5-OXADIAZOL-4-YL) -HETΞROAROMATIC COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-03 | — | — | WO | disclosed |